Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Future Synthesis is a Polish biotechnology company specializing in the custom chemical synthesis of biomolecules, with a primary focus on nucleic acids of both RNA and DNA series. The company provides high-purity synthesis of siRNA, miRNA, antisense oligonucleotides (ASOs), double-stranded and single-stranded RNA/DNA, and short hairpin RNA (shRNA) in quantities ranging from nanograms to grams. Future Synthesis also offers various chain modifications, fluorescent labeling, and analytical services to support research, diagnostic, and therapeutic applications. Additionally, the company participates in collaborative research consortia, such as the NANOFIB and TENTACLES projects, to develop targeted RNA delivery systems and advanced biomaterials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Future Synthesis.